Dianthus Therapeutics (DNTH) Interest Coverage Ratio (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Interest Coverage Ratio of 0.32 for Q3 2025, up 47.67% year-over-year from 0.22 in Q3 2024, and up 85.86% quarter-over-quarter from 2.26 in Q2 2025.
Dianthus Therapeutics (DNTH) Interest Coverage Ratio (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Interest Coverage Ratio history runs 9 years deep, the most recent figure standing at 0.32 for Q3 2025.
- In Q3 2025, Interest Coverage Ratio rose 47.67% year-over-year to 0.32; the TTM figure through Sep 2025 stood at 1.11 (up 34.27% YoY), while the FY2024 annual figure was 0.56, down 43.74% from the prior year.
- Interest Coverage Ratio for Q3 2025 stood at 0.32, up from 2.26 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 0.2 in Q3 2022, with the low at 2355.2 in Q2 2023.
- The 5-year median for Interest Coverage Ratio is 2.26 (2025), against an average of 175.76.
- The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio sank 563126.62% in 2023, then jumped 99.98% in 2024.
- Dianthus Therapeutics' Interest Coverage Ratio stood at 3.88 in 2021, then jumped by 94.88% to 0.2 in 2022, then slumped by 922.39% to 2.03 in 2023, then plunged by 7761.03% to 159.58 in 2024, then jumped by 99.8% to 0.32 in 2025.
- Business Quant data shows DNTH's Interest Coverage Ratio at 0.32 in Q3 2025, 2.26 in Q2 2025, and 2.37 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -0.32 |
| Jun 30, 2025 | -2.26 |
| Mar 31, 2025 | -2.37 |
| Dec 31, 2024 | -159.58 |
| Sep 30, 2024 | -0.61 |
| Jun 30, 2024 | -0.52 |
| Mar 31, 2024 | -0.35 |
| Sep 30, 2023 | -2.03 |
| Jun 30, 2023 | -2,355.20 |
| Mar 31, 2023 | -451.94 |
| Sep 30, 2022 | -0.20 |
| Jun 30, 2022 | -0.42 |
| Mar 31, 2022 | -2.41 |
| Dec 31, 2021 | -3.88 |
| Sep 30, 2021 | -2.45 |
| Jun 30, 2021 | -2.36 |
| Mar 31, 2021 | -1.07 |
| Dec 31, 2020 | -0.26 |
| Sep 30, 2020 | -0.74 |
| Jun 30, 2020 | -0.80 |